How many decades before your stroke hospital gives these to every stroke patient? You have to look at the actual research to see that one of the tests is the Rey Auditory Verbal Learning Test. Then your doctor needs specific protocols that will reverse such brain atrophy and prevent Alzheimers. That is the minimum your doctor is responsible for. DEMAND such competence.
Two Memory Tests Accurately Predict Brain Atrophy, Alzheimer’s Disease
The
use of 2 memory tests assessing episodic memory made the diagnosing of
mild cognitive impairment (MCI) due to Alzheimer’s disease more precise,
and the tests helped identify those individuals with an increased risk
of receiving an Alzheimer’s diagnosis within the next 3 years, according
to a study published in Brain Imaging and Behavior.“The use of 2
memory tests markedly improved the accuracy of the prognosis for an
Alzheimer’s disease diagnosis and brain atrophy in the medial temporal
lobes during a 3-year follow-up period,” said Eero Vuoksimaa, MD,
University of Helsinki, Helsinki, Finland. “The results highlight the
importance of neuropsychological assessment as a cost-effective method
of diagnosing mild cognitive impairment due to Alzheimer’s disease.”
The study utilised data collected in the United States under the Alzheimer’s Disease Neuroimaging Initiative (ADNI), comprising 230 cognitively normal individuals and 394 individuals with MCI on the basis of poor memory performance in 1 episodic memory measure, namely in story recall.
Those with MCI were further divided into 2 groups based on whether their memory performance was impaired only in 1 (story recall) or 2 (story recall and word list recall) tests.
The researchers investigated baseline differences between the groups in terms of Alzheimer’s disease cerebrospinal fluid biomarkers, finding that those who performed poorly in both episodic memory tests more closely resembled Alzheimer’s patients than those who only did poorly in the story recall test.
“During the follow-up stage, brain atrophy in the medial temporal lobes of those who only performed poorly in the story recall test did not differ from the cognitively healthy participants, whereas in those who had poor performance in both the story and word list recall tests, brain atrophy was faster,” said Dr. Vuoksimaa.
Alzheimer’s disease was diagnosed in approximately half of the participants who performed poorly in both episodic memory tests within the 3-year study period, whereas only 16% of those with a poor performance in only 1 memory test received diagnosis of Alzheimer’s Disease.
Several prior studies have shown that word list recall tests predict the risk of Alzheimer’s disease as well as or even better than brain imaging or cerebrospinal fluid biomarkers.
“In this study, we employed age adjusted cut-off points for memory, which produces a diagnostic method directly adaptable to clinical use,” said Dr. Vuoksimaa. “Indeed, more comprehensive neuropsychological assessment including at least 2 episodic memory tests could be introduced as part of the health evaluation of the ageing population, particularly in cases where memory impairment is suspected.”
“Our method could also be used when selecting participants for clinical drug trials,” he added. “When looking for preventive drug therapy for Alzheimer’s disease, it would be important to be able to identify those individuals whose early cognitive impairment is due to Alzheimer’s disease.”
Reference: http://dx.doi.org/10.1007/s11682-018-0019-6
SOURCE: University of Helsinki
The study utilised data collected in the United States under the Alzheimer’s Disease Neuroimaging Initiative (ADNI), comprising 230 cognitively normal individuals and 394 individuals with MCI on the basis of poor memory performance in 1 episodic memory measure, namely in story recall.
Those with MCI were further divided into 2 groups based on whether their memory performance was impaired only in 1 (story recall) or 2 (story recall and word list recall) tests.
The researchers investigated baseline differences between the groups in terms of Alzheimer’s disease cerebrospinal fluid biomarkers, finding that those who performed poorly in both episodic memory tests more closely resembled Alzheimer’s patients than those who only did poorly in the story recall test.
“During the follow-up stage, brain atrophy in the medial temporal lobes of those who only performed poorly in the story recall test did not differ from the cognitively healthy participants, whereas in those who had poor performance in both the story and word list recall tests, brain atrophy was faster,” said Dr. Vuoksimaa.
Alzheimer’s disease was diagnosed in approximately half of the participants who performed poorly in both episodic memory tests within the 3-year study period, whereas only 16% of those with a poor performance in only 1 memory test received diagnosis of Alzheimer’s Disease.
Several prior studies have shown that word list recall tests predict the risk of Alzheimer’s disease as well as or even better than brain imaging or cerebrospinal fluid biomarkers.
“In this study, we employed age adjusted cut-off points for memory, which produces a diagnostic method directly adaptable to clinical use,” said Dr. Vuoksimaa. “Indeed, more comprehensive neuropsychological assessment including at least 2 episodic memory tests could be introduced as part of the health evaluation of the ageing population, particularly in cases where memory impairment is suspected.”
“Our method could also be used when selecting participants for clinical drug trials,” he added. “When looking for preventive drug therapy for Alzheimer’s disease, it would be important to be able to identify those individuals whose early cognitive impairment is due to Alzheimer’s disease.”
Reference: http://dx.doi.org/10.1007/s11682-018-0019-6
SOURCE: University of Helsinki
No comments:
Post a Comment